LEADER 03285nam 22005415 450 001 9910349363203321 005 20251113210637.0 010 $a3-030-19019-6 024 7 $a10.1007/978-3-030-19019-4 035 $a(CKB)4100000008618279 035 $a(MiAaPQ)EBC5811780 035 $a(DE-He213)978-3-030-19019-4 035 $a(PPN)238491773 035 $a(EXLCZ)994100000008618279 100 $a20190702d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMolecular Imaging in Multiple Myeloma /$fedited by Cristina Nanni, Stefano Fanti, Lucia Zanoni 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (138 pages) 311 08$a3-030-19018-8 327 $a1.Multiple Myeloma: clinical aspects -- 2. What does a clinician need from new imaging procedures? -- 3.FDG PET in Multiple Myeloma -- 4. Role of Standard Magnetic Resonance Imaging -- 5.Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A new era for whole body imaging in myeloma? -- 6.CXCR4 imaging in Multiple Myeloma -- 7.PET/CT with Standard NON-FDG Tracers -- 8. The issue of interpretation -- 9. Clinical Teachning Cases: FDG PET/CT . 330 $aThis book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/orevaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists. 606 $aNuclear medicine 606 $aHematology 606 $aOncology 606 $aNuclear Medicine 606 $aHematology 606 $aOncology 615 0$aNuclear medicine. 615 0$aHematology. 615 0$aOncology. 615 14$aNuclear Medicine. 615 24$aHematology. 615 24$aOncology. 676 $a616.99418 676 $a616.99418 702 $aNanni$b Cristina$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFanti$b Stefano$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aZanoni$b Lucia$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910349363203321 996 $aMolecular Imaging in Multiple Myeloma$91737459 997 $aUNINA